In combination, two commonly used heart drugs reverse fat accumulation in the liver, a study in animals has shown.

Using two types of cardiovascular drugs together could help to treat fatty liver disease and reduce the number of severe cases. This is the finding of researchers from the University of Barcelona (UB) ...

A new study suggests a combination of cardiovascular drugs, pemafibrate and telmisartan, may reverse fatty liver disease by reducing fat buildup and improving liver health. This breakthrough offers ...

A case-control study revealed that combinations of drugs for cardiovascular diseases and hypertension were frequently prescribed before a diagnosis of bullous pemphigoid (BP), but the risk associated ...

Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the world, affecting about one-third of the adult population. This disorder is characterized by the ...

Rybelsus is now FDA-approved for managing cardiovascular health. Doctors say oral GLP-1s may reduce heart attack and stroke ...

Two everyday medications, pemafibrate and telmisartan, could offer a safer, faster route to treating fatty liver disease. Scientists in Barcelona found the drug duo reduced liver fat and ...

Semaglutide reduces cardiovascular events by 23% and direct heart disease death risk by 26% compared to dulaglutide in older ...

A type of drug used to help treat heart attacks does not work on the majority of patients and may actually contribute to hospitalization and death for women, new research has found. However, a study ...

Beta blockers, used for decades after heart attacks, provide no benefit for patients with preserved heart function, according to the REBOOT trial. The massive study also found women faced higher risks ...

A commonly prescribed drug could be more effective than aspirin for long-term heart disease prevention. Analysis of nearly 29,000 patients with coronary artery disease (CAD) suggests the blood thinner ...